Prosecution Insights
Last updated: August 06, 2026
Application No. 18/497,645

BIO-ORTHOGONAL DRUG ACTIVATION

Non-Final OA §DOUBLEPATENT
Filed
Oct 30, 2023
Priority
May 16, 2011 — EU 11166241.7 +12 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tagworks Pharmaceuticals B V
OA Round
3 (Non-Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1219 granted / 1631 resolved
+14.7% vs TC avg
Strong +16% interview lift
Without
With
+15.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
46 currently pending
Career history
1666
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
52.8%
+12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1631 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Claims 20-46 are pending in the application. This action is in response to applicants' amendment dated March 31, 2026. Claim 45 has been amended and claims 47-50 have been canceled. Response to Amendment Applicant's arguments filed March 31, 2026 have been fully considered with the following effect: The applicants’ amendments are sufficient to overcome the 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph rejection, labeled paragraph 2) in the last office action, which is hereby withdrawn. The applicant's amendments and arguments are sufficient to overcome the 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph rejection, labeled paragraph 3a) in the last office action, which is hereby withdrawn. With regards to the provisional nonstatutory double patenting rejections the Applicants have requested that each be held in abeyance until there is allowable subject matter. The following provisional nonstatutory double patenting rejections are herein maintained for reasons of record. Claims 45 and 46 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of copending Application No. 17/052,928 (corrected typo from previous office action) (reference application). Claims 45 and 46 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 21 of copending Application No. 17/052,925 (reference application). Claims 45 and 46 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 20-43 of copending Application No. 17/619,796 (reference application). Claims 45 and 46 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 9-11, 15 and 30-33 of copending Application No. 17/619,794 (reference application). Claims 45 and 46 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 5-8, 11, 12, 17, 18 and 31-33 of copending Application No. 17/619,791 (reference application). With regards to the nonstatutory double patenting rejections the Applicants have requested that each be held in abeyance until there is allowable subject matter. The following nonstatutory double patenting rejections are herein maintained for reasons of record. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 9,421,274. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 9,463,256. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 9,427,482. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 9,913,921. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 9,931,408. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 10,004,810. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 10,376,594. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 10,927,139. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 20-34 of U.S. Patent No. 10,967,069. Claims 45 and 46 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-41 of U.S. Patent No. 11,617,799. Election/Restrictions This application contains claims 20-44 drawn to an invention nonelected without traverse in the reply filed on December 16, 2025. A complete reply to this non-final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Oct 30, 2023
Application Filed
Mar 06, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Sep 05, 2025
Response Filed
Oct 01, 2025
Final Rejection mailed — §DOUBLEPATENT
Mar 31, 2026
Request for Continued Examination
Apr 01, 2026
Response after Non-Final Action
May 26, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697342
NON-SURGICAL PREVENTION OF BOAR TAINT AND AGGRESSIVE BEHAVIOR
2y 5m to grant Granted Aug 04, 2026
Patent 12692274
TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES
3y 4m to grant Granted Jul 28, 2026
Patent 12691104
COMPOSITIONS CONTAINING NICOTINAMIDE AND VITAMIN B6 AND METHODS OF USING SUCH COMPOSITIONS FOR TREATING SARCOPENIA AND FRAILTY
3y 3m to grant Granted Jul 28, 2026
Patent 12691105
COMPOSITIONS CONTAINING NICOTINAMIDE AND VITAMIN B6 AND METHODS OF USING SUCH COMPOSITIONS FOR TREATING CACHEXIA OR PRECACHEXIA
3y 3m to grant Granted Jul 28, 2026
Patent 12691125
PREVENTION OF ESTRUS IN SOW AND RUMINANTS
3y 2m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.5%)
2y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1631 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month